CHICAGOResearchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.
The concept of the study is that lymphocyte infusions from the original donor may induce remission. However, this approach may also be complicated by graft-versus-host disease (GVHD).
The researchers will attempt remission induction by infusion of IL-2 activated lymphocytes transduced with the herpes simplex thymidine kinase (HSTK) gene. If severe GVHD occurs, the infused lymphocytes will be killed by adminis-tration of the prodrug ganciclovir(Drug information on ganciclovir) (Cytogene).
Any patient with a hematologic malignancy that relapses after an allogeneic transplant is a candidate for the trial.
For referral of patients to the trial, please contact Richard Burt, MD (312-908-5400) or Ann Traynor, MD (312-908-1609) at Northwestern University Medical School, Chicago; William Drobyski, MD, or William Burns, MD, at the Medical College of Wisconsin, Milwaukee (414-257-5452); or Charles Link, MD, at the Human Gene Therapy Research Institute, Des Moines, Iowa (513-241-8790).